## **Special Issue**

## Novel Challenges and Therapeutic Options for Liver Diseases

## Message from the Guest Editor

Liver diseases represent one of the greatest health problems worldwide and are one of the leading causes of death. Acute and chronic liver diseases and their consequences are the second most common medical care problem. The importance of the early detection and timely treatment of various liver diseases and their primary and secondary prevention should therefore be at the highest priority worldwide. In the last three decades, in particular, groundbreaking developments in the diagnosis and therapy of liver diseases have been made thanks to scientific advances. In this Special Issue, research topics range from viral diseases to autoimmune, vascular, metabolic, and genetic diseases to liver cirrhosis and its subsequent complications, acute chronic liver failure, and the development of primary liver cell carcinomas are warmly welcome. Topics such as therapeutic immunization, cell-based tumor therapy, liver-guts interaction based on the microbiome, and precision medicine using the example of the molecular profiling of tumors will be also covered.

#### **Guest Editor**

Prof. Dr. Guido Gerken

- Professor Emeritus, Department of Gastroenterology and Hepatology, University Hospital, University of Duisburg-Essen, D-45122 Essen, Germany
- 2. Senior Consultant, Helios Klinikum Niederberg, 42549 Velbert, Germany

## Deadline for manuscript submissions

closed (1 February 2024)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/144716

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

#### Editor-in-Chief

#### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

### **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

